Evidence map›Paper›PMID 40979139›Full record

ReviewNuclear medicine and molecular imaging2025

Real Challenges Before, During, and after Establishing a Theranostics Center in Developing Countries.

Patricia Bautista-Peñalosa

Abstract readReview
In one paragraph

Review in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Bridging the Gap in Theranostics: Where Do We Stand?Nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Patricia Bautista-PeñalosaDepartment of Nuclear Medicine and Theranostics, St. Luke's Medical Center - Global City, Taguig City, Metro Manila Philippines.ORCID 0000-0003-4003-7185

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theranostics, the combined use of radiopharmaceuticals for diagnosis and therapy, has seen a significant evolution, accelerated by its application in prostate cancer. While this field has grown exponentially over the past decade, its implementation remains fraught with challenges, especially in developing countries. These challenges span three stages: pre-establishment, establishment, and post-establishment of theranostics centers. This article explores these obstacles and offers insights into overcoming them. In the pre-establishment phase, key barriers include limited government funding, lack of administrative support, and personal risks. During establishment, multitasking, the absence of trained personnel, and resource shortages are prominent hurdles. Post-establishment trials include overcoming colonial mentality, limited patient access due to financial constraints, logistical difficulties, and a lack of research capacity, among others. Despite these tests, successful establishment of theranostics centers is possible through strong leadership, rigorous training, international collaboration, and a patient-centered approach. The experience of the Philippines illustrates that, while the road is challenging, it is ultimately achievable with clear vision, unrelenting dedication, and the stakeholders' cooperation.

Indexed as

ChallengesDeveloping countriesTheranostics center

Identifiers

PMID40979139
PMCPMC12446168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.